TW201613958A - MIC-1 fusion proteins and uses thereof - Google Patents
MIC-1 fusion proteins and uses thereofInfo
- Publication number
- TW201613958A TW201613958A TW104119532A TW104119532A TW201613958A TW 201613958 A TW201613958 A TW 201613958A TW 104119532 A TW104119532 A TW 104119532A TW 104119532 A TW104119532 A TW 104119532A TW 201613958 A TW201613958 A TW 201613958A
- Authority
- TW
- Taiwan
- Prior art keywords
- mic
- compounds
- fusion proteins
- relates
- terminus
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title abstract 4
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14173664 | 2014-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201613958A true TW201613958A (en) | 2016-04-16 |
Family
ID=51032955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104119532A TW201613958A (en) | 2014-06-24 | 2015-06-17 | MIC-1 fusion proteins and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9272019B2 (https=) |
| EP (1) | EP3160496B1 (https=) |
| JP (1) | JP6696915B2 (https=) |
| KR (1) | KR20170020383A (https=) |
| CN (1) | CN106459222A (https=) |
| AR (1) | AR100945A1 (https=) |
| AU (1) | AU2015279525A1 (https=) |
| BR (1) | BR112016029848A2 (https=) |
| CA (1) | CA2952293A1 (https=) |
| IL (1) | IL249327A0 (https=) |
| MX (1) | MX2016016063A (https=) |
| RU (1) | RU2017101436A (https=) |
| TW (1) | TW201613958A (https=) |
| WO (1) | WO2015197446A1 (https=) |
| ZA (1) | ZA201608214B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI853223B (zh) * | 2016-05-10 | 2024-08-21 | 美商健生生物科技公司 | Gdf15融合蛋白及其用途 |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103533951B (zh) | 2011-04-08 | 2017-04-19 | 安姆根有限公司 | 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法 |
| TWI648401B (zh) | 2013-07-31 | 2019-01-21 | 安美基公司 | 生長分化因子１５（ｇｄｆ－１５）構築體 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CN108367053A (zh) | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
| CN109414471A (zh) * | 2016-05-24 | 2019-03-01 | 诺和诺德股份有限公司 | Mic-1化合物及其用途 |
| GB201615844D0 (en) * | 2016-09-16 | 2016-11-02 | Genagon Therapeutics Ab | Agents for use in therapy |
| EP3551214B1 (en) * | 2016-12-06 | 2024-03-13 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
| GB201700553D0 (en) * | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| MA50141A (fr) | 2017-04-20 | 2020-07-29 | Novo Nordisk As | Procédés de purification de protéines de fusion d'albumine |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| CN111163795A (zh) | 2017-09-10 | 2020-05-15 | 诺沃挪第克公司 | 用于治疗肥胖症的mic-1和glp-1 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CR20200510A (es) | 2018-04-09 | 2020-11-26 | Amgen Inc | Protreínas de fusión del factor de diferenciación de crecimiento 15 |
| ES2972119T3 (es) | 2018-08-10 | 2024-06-11 | Alexion Pharma Inc | Cicatrización ósea en implantes utilizando fosfatasa alcalina |
| CA3106948A1 (en) | 2018-08-10 | 2020-02-13 | Novartis Ag | Gfral extracellular domains and methods of use |
| EP3870211B1 (en) | 2018-10-22 | 2025-01-08 | Janssen Sciences Ireland Unlimited Company | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
| US12544427B2 (en) | 2019-10-04 | 2026-02-10 | Amgen Inc. | Use of GDF15 for treating cardiometabolic syndrome and other conditions |
| BR112022010227A2 (pt) * | 2019-11-26 | 2022-09-13 | Yuhan Corp | Proteína de fusão gdf15 de ação prolongada e composição farmacêutica compreendendo a mesma |
| KR20220111693A (ko) * | 2019-12-09 | 2022-08-09 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법 |
| BR112022011540A2 (pt) * | 2019-12-11 | 2022-09-06 | Lg Chemical Ltd | Polipeptídeo de fusão compreendendo gdf15, composição farmacêutica que compreende o mesmo, dímero e método de preparação do dito polipeptídeo, método para aumentar a estabilidade in vivo de gdf15, molécula de ácido nucleico, vetor e célula recombinantes e uso terapêutico do dito polipeptídeo e dímero |
| JP2023512423A (ja) * | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| WO2021194257A1 (ko) * | 2020-03-25 | 2021-09-30 | (주) 업테라 | 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템 |
| KR102195740B1 (ko) * | 2020-03-25 | 2020-12-28 | 서울대학교산학협력단 | 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템 |
| WO2022089435A1 (en) | 2020-10-27 | 2022-05-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of gdf15 and use thereof |
| CN112694520B (zh) * | 2020-12-02 | 2023-01-17 | 图凌(杭州)生物医药有限公司 | 一种人工多肽hm、其抗体及在病理检测中的应用 |
| US12083169B2 (en) | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| EP4476212A1 (en) | 2022-02-10 | 2024-12-18 | Novartis AG | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| EP1734986B1 (en) | 2004-04-13 | 2015-11-11 | St Vincent's Hospital Sydney Limited | Method for modulating appetite |
| SI1751184T1 (sl) * | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fuzijski proteini |
| EP1771467A2 (en) * | 2004-07-26 | 2007-04-11 | Asterion Limited | Linkers |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| JP2015506373A (ja) * | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子１５（ｇｄｆ−１５）ポリペプチド |
| JP6254146B2 (ja) * | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| TWI648401B (zh) | 2013-07-31 | 2019-01-21 | 安美基公司 | 生長分化因子１５（ｇｄｆ－１５）構築體 |
-
2015
- 2015-06-17 EP EP15730140.9A patent/EP3160496B1/en not_active Withdrawn - After Issue
- 2015-06-17 JP JP2016574944A patent/JP6696915B2/ja not_active Expired - Fee Related
- 2015-06-17 MX MX2016016063A patent/MX2016016063A/es unknown
- 2015-06-17 CN CN201580033507.XA patent/CN106459222A/zh not_active Withdrawn
- 2015-06-17 WO PCT/EP2015/063596 patent/WO2015197446A1/en not_active Ceased
- 2015-06-17 US US14/742,159 patent/US9272019B2/en not_active Expired - Fee Related
- 2015-06-17 TW TW104119532A patent/TW201613958A/zh unknown
- 2015-06-17 RU RU2017101436A patent/RU2017101436A/ru unknown
- 2015-06-17 CA CA2952293A patent/CA2952293A1/en not_active Withdrawn
- 2015-06-17 BR BR112016029848A patent/BR112016029848A2/pt not_active Application Discontinuation
- 2015-06-17 KR KR1020167037059A patent/KR20170020383A/ko not_active Withdrawn
- 2015-06-17 AU AU2015279525A patent/AU2015279525A1/en not_active Withdrawn
- 2015-06-23 AR ARP150102007A patent/AR100945A1/es active IP Right Grant
-
2016
- 2016-01-19 US US15/000,637 patent/US9956264B2/en not_active Expired - Fee Related
- 2016-11-28 ZA ZA2016/08214A patent/ZA201608214B/en unknown
- 2016-12-01 IL IL249327A patent/IL249327A0/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI853223B (zh) * | 2016-05-10 | 2024-08-21 | 美商健生生物科技公司 | Gdf15融合蛋白及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016029848A2 (pt) | 2017-10-24 |
| EP3160496A1 (en) | 2017-05-03 |
| US20160015784A1 (en) | 2016-01-21 |
| JP6696915B2 (ja) | 2020-05-20 |
| US20160129083A1 (en) | 2016-05-12 |
| IL249327A0 (en) | 2017-02-28 |
| AR100945A1 (es) | 2016-11-09 |
| CA2952293A1 (en) | 2015-12-30 |
| KR20170020383A (ko) | 2017-02-22 |
| MX2016016063A (es) | 2017-03-10 |
| US9956264B2 (en) | 2018-05-01 |
| AU2015279525A1 (en) | 2016-12-15 |
| EP3160496B1 (en) | 2021-03-03 |
| CN106459222A (zh) | 2017-02-22 |
| WO2015197446A1 (en) | 2015-12-30 |
| RU2017101436A3 (https=) | 2019-02-13 |
| US9272019B2 (en) | 2016-03-01 |
| ZA201608214B (en) | 2018-11-28 |
| JP2017528419A (ja) | 2017-09-28 |
| RU2017101436A (ru) | 2018-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| SG11201702813VA (en) | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | |
| MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| MX2017006866A (es) | Pares de unión para producción de péptidos. | |
| MX2016010951A (es) | Proteinas de fc multimericas. | |
| PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
| MX360816B (es) | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. | |
| WO2014026054A3 (en) | CD20 scFv-ELPs METHODS AND THERAPEUTICS | |
| PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| MX384236B (es) | Productos farmaceuticos mejorados de peptido para resistencia a la insulina | |
| MX378431B (es) | Uso terapèutico de proteìnas morfogenèticas òseas. | |
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| MX2019014504A (es) | Inmunoglobulinas de union a agrecano. | |
| MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
| MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
| MX2020007628A (es) | Composiciones y metodos de uso. | |
| PH12017500742A1 (en) | Statherin peptides | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| WO2015043566A8 (de) | Zyklische, amyloid-beta-bindende peptide und deren verwendung |